AR060449A1 - Inhibicion mediada por arni de afecciones relacionadas con el receptor de histamina h1 - Google Patents
Inhibicion mediada por arni de afecciones relacionadas con el receptor de histamina h1Info
- Publication number
- AR060449A1 AR060449A1 ARP070101582A ARP070101582A AR060449A1 AR 060449 A1 AR060449 A1 AR 060449A1 AR P070101582 A ARP070101582 A AR P070101582A AR P070101582 A ARP070101582 A AR P070101582A AR 060449 A1 AR060449 A1 AR 060449A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- nucleotides
- histamine
- penultimate
- region
- Prior art date
Links
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 title 2
- 241000320892 Clerodendrum phlomidis Species 0.000 title 1
- 229940125365 angiotensin receptor blocker-neprilysin inhibitor Drugs 0.000 title 1
- 229960001340 histamine Drugs 0.000 title 1
- 239000002773 nucleotide Substances 0.000 abstract 7
- 125000003729 nucleotide group Chemical group 0.000 abstract 7
- 108020004999 messenger RNA Proteins 0.000 abstract 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 4
- 102000003834 Histamine H1 Receptors Human genes 0.000 abstract 3
- 108090000110 Histamine H1 Receptors Proteins 0.000 abstract 3
- 102100032509 Histamine H1 receptor Human genes 0.000 abstract 3
- 101001016841 Homo sapiens Histamine H1 receptor Proteins 0.000 abstract 3
- 230000002452 interceptive effect Effects 0.000 abstract 3
- 206010010744 Conjunctivitis allergic Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 206010015943 Eye inflammation Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 abstract 1
- 208000002205 allergic conjunctivitis Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000024998 atopic conjunctivitis Diseases 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000009368 gene silencing by RNA Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 206010039083 rhinitis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79162306P | 2006-04-13 | 2006-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR060449A1 true AR060449A1 (es) | 2008-06-18 |
Family
ID=38610324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070101582A AR060449A1 (es) | 2006-04-13 | 2007-04-13 | Inhibicion mediada por arni de afecciones relacionadas con el receptor de histamina h1 |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US8017592B2 (enExample) |
| EP (2) | EP2674493B1 (enExample) |
| JP (1) | JP5473594B2 (enExample) |
| AR (1) | AR060449A1 (enExample) |
| TW (1) | TW200808361A (enExample) |
| WO (1) | WO2007121156A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2674493B1 (en) | 2006-04-13 | 2017-12-27 | Arrowhead Research Corporation | RNAi-mediated inhibition of histamine receptor H1-related conditions |
| US10787664B2 (en) * | 2015-05-26 | 2020-09-29 | City Of Hope | Compounds of chemically modified oligonucleotides and methods of use thereof |
| BR112018072511A2 (pt) * | 2016-05-09 | 2019-03-12 | Biogaia Ab | métodos para selecionar uma cepa bacteriana e para profilaxia, inibição e/ou tratamento de uma alergia, cepa, e, composição antialérgica |
| EP4306655A4 (en) * | 2021-08-04 | 2024-08-21 | Hangzhou Zheda Dixun Biological Gene Engineering Co., Ltd | PRIMER-PROBE SET, KIT AND DETECTION METHOD FOR DETECTING HUMAN HISTAMINE RECEPTOR HRH1 mRNA |
| CN113604557A (zh) * | 2021-08-04 | 2021-11-05 | 杭州浙大迪迅生物基因工程有限公司 | 一种人组胺受体HRH1 mRNA检测引物探针组、试剂盒和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2284266T3 (da) * | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| AU2003224132A1 (en) * | 2003-04-24 | 2004-11-19 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
| CA2532084A1 (en) * | 2003-07-11 | 2005-02-03 | Oregon Health And Science University | Methods of treatment and diagnosis using modulators of virus-induced cellular gene sequences |
| WO2005028667A1 (ja) * | 2003-09-19 | 2005-03-31 | Riken | ヒト肥満細胞で発現するｇ蛋白質共役型受容体を標的とした薬剤およびそのスクリーニング方法 |
| AU2005248147A1 (en) * | 2004-05-11 | 2005-12-08 | Alphagen Co., Ltd. | Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same |
| US20070213286A1 (en) * | 2005-09-12 | 2007-09-13 | The Trustees Of Columbia University In The City Of New York | Inhibitors of dynein or lissencephaly 1, and methods of using same for treatment of neuronal disorders |
| EP2674493B1 (en) * | 2006-04-13 | 2017-12-27 | Arrowhead Research Corporation | RNAi-mediated inhibition of histamine receptor H1-related conditions |
-
2007
- 2007-04-10 EP EP13172325.6A patent/EP2674493B1/en active Active
- 2007-04-10 EP EP07760365A patent/EP2003971A4/en not_active Withdrawn
- 2007-04-10 JP JP2009505565A patent/JP5473594B2/ja not_active Expired - Fee Related
- 2007-04-10 US US12/296,565 patent/US8017592B2/en active Active
- 2007-04-10 WO PCT/US2007/066287 patent/WO2007121156A2/en not_active Ceased
- 2007-04-12 TW TW096112906A patent/TW200808361A/zh unknown
- 2007-04-13 AR ARP070101582A patent/AR060449A1/es unknown
-
2011
- 2011-06-30 US US13/173,512 patent/US8222227B2/en active Active
-
2012
- 2012-06-11 US US13/493,098 patent/US8618278B2/en active Active
-
2013
- 2013-11-22 US US14/087,344 patent/US9206428B2/en active Active
-
2015
- 2015-11-02 US US14/929,486 patent/US9745585B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9745585B2 (en) | 2017-08-29 |
| WO2007121156A3 (en) | 2008-11-06 |
| US9206428B2 (en) | 2015-12-08 |
| US20140088172A1 (en) | 2014-03-27 |
| JP5473594B2 (ja) | 2014-04-16 |
| EP2674493B1 (en) | 2017-12-27 |
| US20110269822A1 (en) | 2011-11-03 |
| EP2674493A1 (en) | 2013-12-18 |
| US8222227B2 (en) | 2012-07-17 |
| US20160053270A1 (en) | 2016-02-25 |
| TW200808361A (en) | 2008-02-16 |
| US20120264809A1 (en) | 2012-10-18 |
| US20090274631A1 (en) | 2009-11-05 |
| US8618278B2 (en) | 2013-12-31 |
| JP2009533466A (ja) | 2009-09-17 |
| US8017592B2 (en) | 2011-09-13 |
| EP2003971A2 (en) | 2008-12-24 |
| WO2007121156A2 (en) | 2007-10-25 |
| WO2007121156A8 (en) | 2011-05-19 |
| EP2003971A4 (en) | 2010-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR060448A1 (es) | Inhibicion mediada por rnai de afecciones inflamatorias relacionadas con tirosina quinasa del bazo | |
| JP2018533954A5 (enExample) | ||
| BR112014017650A8 (pt) | Uso de ésteres de forbol para tratar ou prevenir um ou mais dos sintomas da doença de parkinson | |
| CL2011002787A1 (es) | Compuestos derivados de 1-cianoetilheterociclilcarboxamida sustituidos, inhibidores de dipeptidilpeptidasa i (dppi) o catepsina c; composicion farmaceutica; combinacion faramceutica; y su uso en el tratamiento del asma, la enfermedad obstructiva cronica o la rinitis alergica. | |
| AR060449A1 (es) | Inhibicion mediada por arni de afecciones relacionadas con el receptor de histamina h1 | |
| WO2009044392A3 (en) | Novel sirna structures | |
| WO2008050329A3 (en) | Novel sirnas and methods of use thereof | |
| AR083787A1 (es) | Composicion farmaceutica que comprende un inhibidor del transportador 2 de sodio-glucosa (sglt2) y una insulina, procedimientos de tratamiento y usos de la misma | |
| CL2007002274A1 (es) | Compuestos derivados del acido (3-amino-1,2,3,4-tetrahidro-9h-carbazol-9-il)-acetico; composicion farmaceutica; y uso para la prevencion y/o tratamiento de enfermedades alergicas e inmunes, tales como asma, epoc y rinitis entre otras. | |
| BR112012011381B8 (pt) | oligonucleotídeo antisenso antiviral isolado e composição farmacêutica compreendendo o mesmo | |
| EA200802166A1 (ru) | Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью | |
| CO6351742A2 (es) | Compuestos organicos para la cicatrizacion de heridas | |
| CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
| BRPI0613859B8 (pt) | inibidores da comt, seus usos, e composição farmacêutica | |
| ECSP088298A (es) | Modulacion de la expresion del receptor glucocorticoide | |
| BR112012016797A2 (pt) | intensificador dinâmico de baixo utilizando compressor com equalizador incorporado | |
| ECSP099061A (es) | Moduladores de benzofuro- y benzotienopirimidina | |
| WO2007128086A3 (en) | Novel viral replication inhibitor | |
| MX2011011656A (es) | Uso de los inhibidores de la fosfodiesterasa 7 para el tratamiento de trastornos del movimiento. | |
| AR067395A1 (es) | Inhibicion de htra1 mediada por iarn para el tratamiento de la degeneracion macular | |
| WO2007143557A3 (en) | Compounds and methods for treating mammalian gastrointestinal parasitic infections | |
| AR064016A1 (es) | Inhibicion mediada por arni de acuaporina 4 para tratamiento de afecciones relacionadas con pio | |
| CL2020002563A1 (es) | Uso de inhibidores de fubp1 para el tratamiento de infección de virus de hepatitis b | |
| BRPI1016257B8 (pt) | composições compreendendo finafloxacina para tratamento de infecções óticas | |
| PE20250074A1 (es) | Composiciones y metodos para inhibir la expresion del componente 1 de reduccion de amidoxima mitocondrial (marc1) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |